Hiroyuki Uchida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2695655/publications.pdf

Version: 2024-02-01

321 papers 6,789 citations

42 h-index 110387 64 g-index

341 all docs

341 does citations

times ranked

341

7271 citing authors

#	Article	IF	CITATIONS
1	Kynurenine pathway in depression: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2018, 90, 16-25.	6.1	199
2	Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2014, 40, 1385-1403.	4.3	166
3	The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. American Journal of Psychiatry, 2017, 174, 840-849.	7.2	155
4	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 2012, 197, 1-6.	3. 3	148
5	Persistence and compliance to antidepressant treatment in patients with depression: A chart review. BMC Psychiatry, 2009, 9, 38.	2.6	147
6	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.7	135
7	Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. International Journal of Neuropsychopharmacology, 2014, 17, 1083-1093.	2.1	131
8	Dopamine D2 Receptor Occupancy and Clinical Effects. Journal of Clinical Psychopharmacology, 2011, 31, 497-502.	1.4	117
9	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. Schizophrenia Bulletin, 2013, 39, 564-574.	4.3	109
10	Increased Antipsychotic Sensitivity in Elderly Patients. Journal of Clinical Psychiatry, 2009, 70, 397-405.	2.2	104
11	Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. Schizophrenia Research, 2012, 134, 219-225.	2.0	100
12	Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophrenia Research, 2011, 133, 54-62.	2.0	99
13	Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin, 2011, 37, 788-799.	4.3	94
14	Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study. Schizophrenia Bulletin, 2013, 39, 993-998.	4.3	92
15	Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. International Journal of Neuropsychopharmacology, 2004, 7, 133-142.	2.1	90
16	Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry, 2015, 20, 1151-1160.	7.9	78
17	Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs. Journal of Clinical Psychopharmacology, 2011, 31, 318-325.	1.4	77
18	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. JAMA Psychiatry, 2015, 72, 927.	11.0	77

#	Article	IF	CITATIONS
19	Language Barriers and Access to Psychiatric Care: A Systematic Review. Psychiatric Services, 2015, 66, 798-805.	2.0	68
20	Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Canadian Journal of Psychiatry, 2015, 60, 215-222.	1.9	63
21	Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. Schizophrenia Research, 2016, 171, 86-91.	2.0	63
22	NO-Rich Diet for Lifestyle-Related Diseases. Nutrients, 2015, 7, 4911-4937.	4.1	62
23	Effects of Weekly One-Hour Hatha Yoga Therapy on Resilience and Stress Levels in Patients with Schizophrenia-Spectrum Disorders: An Eight-Week Randomized Controlled Trial. Journal of Alternative and Complementary Medicine, 2014, 20, 823-830.	2.1	61
24	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Molecular Psychiatry, 2022, 27, 744-757.	7.9	60
25	Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 259-264.	4.8	59
26	Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. American Journal of Geriatric Psychiatry, 2009, 17, 255-263.	1.2	58
27	Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. Therapeutic Drug Monitoring, 2009, 31, 360-366.	2.0	57
28	The evolution of antipsychotic switch and polypharmacy in natural practice â€" A longitudinal perspective. Schizophrenia Research, 2011, 130, 40-46.	2.0	57
29	Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and selfâ€esteem. Acta Psychiatrica Scandinavica, 2016, 134, 360-367.	4.5	56
30	Dietary nitrite supplementation improves insulin resistance in type 2 diabetic KKAy mice. Nitric Oxide - Biology and Chemistry, 2015, 44, 31-38.	2.7	53
31	Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. Journal of Psychiatric Research, 2017, 91, 26-35.	3.1	52
32	Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Psychopharmacology, 2017, 234, 2453-2461.	3.1	52
33	Augmentation of atypical antipsychotics with valproic acid. An open″abel study for most difficult patients with schizophrenia. Human Psychopharmacology, 2009, 24, 628-638.	1.5	51
34	Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. Schizophrenia Research, 2016, 175, 148-153.	2.0	50
35	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology, 2020, 45, 632-640.	5.4	50
36	Visualization of AMPA receptors in living human brain with positron emission tomography. Nature Medicine, 2020, 26, 281-288.	30.7	50

#	Article	IF	CITATIONS
37	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology, 2007, 195, 285-295.	3.1	49
38	Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Schizophrenia Research, 2020, 215, 8-16.	2.0	49
39	Effects of yoga therapy on postural stability in patients with schizophrenia-spectrum disorders: A single-blind randomized controlled trial. Journal of Psychiatric Research, 2013, 47, 1744-1750.	3.1	48
40	Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. European Psychiatry, 2017, 46, 42-47.	0.2	47
41	Interventions to reduce antipsychotic polypharmacy: A systematic review. Schizophrenia Research, 2013, 143, 215-220.	2.0	46
42	Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia. Journal of Clinical Psychiatry, 2008, 69, 1281-1286.	2.2	46
43	Effects of Age and Age of Onset on Prescribed Antipsychotic Dose in Schizophrenia Spectrum Disorders: A Survey of 1,418 Patients in Japan. American Journal of Geriatric Psychiatry, 2008, 16, 584-593.	1.2	45
44	Predicting Age-Specific Dosing of Antipsychotics. Clinical Pharmacology and Therapeutics, 2009, 86, 360-362.	4.7	45
45	Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia. American Journal of Geriatric Psychiatry, 2012, 20, 53-60.	1.2	44
46	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Molecular Psychiatry, 2022, 27, 2950-2967.	7.9	44
47	Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open″abel trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology, 2008, 23, 455-463.	1.5	43
48	D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 571-575.	1.4	41
49	Trajectories of individual symptoms in remitters versus non-remitters with depression. Journal of Affective Disorders, 2013, 151, 506-513.	4.1	41
50	Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology, 2020, 45, 887-901.	5.4	41
51	Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. British Journal of Psychiatry, 2011, 199, 275-280.	2.8	40
52	Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Psychiatry Research, 2015, 227, 265-269.	3.3	40
53	Quetiapine Extended-Release Versus Immediate-Release Formulation. Journal of Clinical Psychiatry, 2008, 69, 81-86.	2.2	40
54	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1983-1989.	4.8	38

#	Article	IF	Citations
55	Dental conditions in inpatients with schizophrenia: A large-scale multi-site survey. BMC Oral Health, 2012, 12, 32.	2.3	38
56	Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan. Journal of Anxiety Disorders, 2009, 23, 477-481.	3.2	37
57	Oral nitrite ameliorates dextran sulfate sodium-induced acute experimental colitis in mice. Nitric Oxide - Biology and Chemistry, 2010, 23, 65-73.	2.7	36
58	Clozapine and Global Cognition in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 431-436.	1.4	35
59	Sensitivity to Antipsychotic Drugs in Older Adults. Current Psychiatry Reports, 2010, 12, 28-33.	4.5	35
60	Incidence of Deep Vein Thrombosis in Restrained Psychiatric Patients. Psychosomatics, 2014, 55, 69-75.	2.5	35
61	Dietary nitrite supplementation attenuates cardiac remodeling in I -NAME-induced hypertensive rats. Nitric Oxide - Biology and Chemistry, 2017, 67, 1-9.	2.7	35
62	Resilience and spirituality in patients with depression and their family members: A cross-sectional study. Comprehensive Psychiatry, 2017, 77, 53-59.	3.1	34
63	A tailored nextâ€generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Cancer Science, 2020, 111, 3902-3911.	3.9	34
64	A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2008, 28, 540-543.	1.4	32
65	Influence of Anticholinergic Activity in Serum on Clinical Symptoms of Alzheimer's Disease. Neuropsychobiology, 2011, 63, 147-153.	1.9	32
66	Effects of discontinuing benzodiazepineâ€derivative hypnotics on postural sway and cognitive functions in the elderly. International Journal of Geriatric Psychiatry, 2010, 25, 1259-1265.	2.7	31
67	Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease. Psychogeriatrics, 2010, 10, 34-38.	1.2	31
68	Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. Journal of Affective Disorders, 2018, 238, 399-404.	4.1	31
69	Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacology Bulletin, 2011, 44, 32-60.	0.0	31
70	Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 2003, 18, 323-329.	1.7	30
71	Dietary nitrite inhibits early glomerular injury in streptozotocin-induced diabetic nephropathy in rats. Nitric Oxide - Biology and Chemistry, 2007, 17, 75-81.	2.7	30
72	Pharmacological management of depression: Japanese expert consensus. Journal of Affective Disorders, 2020, 266, 626-632.	4.1	30

#	Article	IF	Citations
73	A review on schizophrenia and relapse—a quest for userâ€friendly psychopharmacotherapy. Human Psychopharmacology, 2014, 29, 414-426.	1.5	29
74	Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology, 2014, 34, 728-735.	1.4	29
75	Incidence of deep vein thrombosis in catatonic patients: A chart review. Psychiatry Research, 2016, 241, 61-65.	3.3	29
76	Measurements of resonant scattering in the Perseus Cluster core with Hitomi SXS. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	29
77	A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 361-369.	4.8	28
78	Dosing of antipsychotics in schizophrenia across the life-spectrum. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 917-920.	4.8	28
79	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. Psychiatry Research, 2013, 209, 406-411.	3.3	28
80	Improvement of spectroscopic performance using a charge-sensitive amplifier circuit for an X-ray astronomical SOI pixel detector. Journal of Instrumentation, 2015, 10, C06005-C06005.	1.2	28
81	Novel rating scales for schizophrenia — Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophrenia Research, 2008, 106, 328-336.	2.0	27
82	Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. Schizophrenia Research, 2014, 153, 184-188.	2.0	27
83	Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international crossâ€sectional study. Acta Psychiatrica Scandinavica, 2018, 137, 316-327.	4.5	27
84	Hitomi observation of radio galaxy NGC 1275: The first X-ray microcalorimeter spectroscopy of Fe-Kα line emission from an active galactic nucleus. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	27
85	Management of Schizophrenia in Late Life with Antipsychotic Medications. Drugs and Aging, 2011, 28, 961-980.	2.7	26
86	Effects of aging on 5â€HT _{2A} R binding: a HRRT PET study with and without partial volume corrections. International Journal of Geriatric Psychiatry, 2011, 26, 1300-1308.	2.7	26
87	The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophrenia Research, 2013, 147, 383-386.	2.0	26
88	Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 178-182.	4.8	25
89	Factors Associated With Delirium Following Electroconvulsive Therapy. Journal of ECT, 2019, 35, 279-287.	0.6	25
90	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. American Journal of Geriatric Psychiatry, 2014, 22, 1007-1016.	1.2	24

#	Article	IF	Citations
91	Patients' attitudes toward side effects of antidepressants: an Internet survey. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 103-109.	3.2	23
92	Predicting Plasma Concentration of Risperidone Associated With Dosage Change. Therapeutic Drug Monitoring, 2012, 34, 182-187.	2.0	23
93	Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 682-685.	1.4	23
94	Effectiveness and safety of long-term benzodiazepine use in anxiety disorders. International Clinical Psychopharmacology, 2019, 34, 211-221.	1.7	23
95	Recurrent Episodes of Perceptual Alteration in Patients Treated With Antipsychotic Agents. Journal of Clinical Psychopharmacology, 2003, 23, 496-499.	1.4	22
96	Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: Oneâ€year followâ€up study. Psychiatry and Clinical Neurosciences, 2010, 64, 104-106.	1.8	22
97	Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry and Clinical Neurosciences, 2011, 65, 676-678.	1.8	22
98	Dietary nitrite reverses features of postmenopausal metabolic syndrome induced by high-fat diet and ovariectomy in mice. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E300-E308.	3.5	22
99	Effects of chair yoga therapy on physical fitness in patients with psychiatric disorders: A 12-week single-blind randomized controlled trial. Journal of Psychiatric Research, 2017, 94, 194-201.	3.1	22
100	Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 182-187.	4.8	21
101	Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. General Hospital Psychiatry, 2013, 35, 649-652.	2.4	21
102	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2017, 43, sbw171.	4.3	21
103	Detection of polarized gamma-ray emission from the Crab nebula with the Hitomi Soft Gamma-ray Detector. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	21
104	White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109871.	4.8	21
105	Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2005, 25, 545-551.	1.4	20
106	Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology, 2005, 181, 566-575.	3.1	20
107	Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry and Clinical Neurosciences, 2009, 63, 244-246.	1.8	20
108	Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. Psychiatry and Clinical Neurosciences, 2011, 65, 299-299.	1.8	20

#	Article	IF	CITATIONS
109	Localized recombining plasma in G166.0+4.3: A supernova remnant with an unusual morphology. Publication of the Astronomical Society of Japan, 2017, 69, .	2.5	20
110	Temperature structure in the Perseus cluster core observed with Hitomi. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	20
111	Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. Journal of the Neurological Sciences, 2012, 315, 137-140.	0.6	19
112	Japanese versions of the Executive Interview (J-EXIT25) and the Executive Clock Drawing Task (J-CLOX) for older people. International Psychogeriatrics, 2014, 26, 1387-1397.	1.0	19
113	Predictors of Clinical Worsening After a Switch to Aripiprazole in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 394-395.	1.4	18
114	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2017, 25, 1-10.	1.2	18
115	Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms. Schizophrenia Research, 2021, 236, 142-155.	2.0	18
116	Soft X-ray Imager aboard Hitomi (ASTRO-H). Journal of Astronomical Telescopes, Instruments, and Systems, 2018, 4, 1.	1.8	18
117	Reintroduction of Clozapine After Perforation of the Large Intestineâ€"A Case Report and Review of the Literature. Annals of Pharmacotherapy, 2013, 47, e31-e31.	1.9	17
118	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11C]-raclopride PET study. Schizophrenia Research, 2015, 164, 263-267.	2.0	17
119	Naming for Psychotropic Drugs: Dilemma and Challenge. Pharmacopsychiatry, 2017, 50, 1-2.	3.3	17
120	How Successful Are Physicians in Eliciting the Truth From Their Patients?. Journal of Clinical Psychiatry, 2012, 73, 311-317.	2.2	17
121	A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable. Journal of Clinical Psychiatry, 2012, 73, 1147-1152.	2.2	17
122	Melancholic and reactive depression: a reappraisal of old categories. BMC Psychiatry, 2013, 13, 311.	2.6	16
123	Association between antidepressant side effects and functional impairment in patients with major depressive disorders. Psychiatry Research, 2013, 210, 127-133.	3.3	16
124	Dopamine D2/3Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Schizophrenia Bulletin, 2015, 42, sbv106.	4.3	16
125	Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disorders, 2020, 22, 822-830.	1.9	16
126	Antipsychotic-Induced Paroxysmal Perceptual Alteration. American Journal of Psychiatry, 2003, 160, 2243-a-2244.	7.2	16

#	Article	IF	CITATIONS
127	Impact of Once-Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes. Journal of Clinical Psychiatry, 2014, 75, 506-511.	2.2	16
128	Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 2003, 18, 323-329.	1.7	15
129	Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. Schizophrenia Research, 2009, 109, 130-133.	2.0	15
130	Clinical and Demographic Characteristics Associated With Postural Instability in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 16-21.	1.4	15
131	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology, 2013, 228, 43-51.	3.1	15
132	Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. Molecular and Clinical Oncology, 2017, 6, 105-110.	1.0	15
133	<p>Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 781-787.	2.2	15
134	Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. Journal of Psychiatric Research, 2015, 68, 151-156.	3.1	14
135	Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics. Journal of Clinical Psychopharmacology, 2018, 38, 582-589.	1.4	14
136	Model-Guided Antipsychotic Dose Reduction in Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 329-335.	1.4	14
137	Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109756.	4.8	14
138	Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D ₂ Receptor Occupancy in Stable Patients With Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 1209-1214.	2.2	14
139	Reducing the Dose of Antipsychotic Agents Ameliorates Visual Hypersensitivity Attack. Journal of Clinical Psychopharmacology, 2006, 26, 50-55.	1.4	13
140	Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 525-527.	1.5	13
141	How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective. Pharmacopsychiatry, 2012, 45, 133-137.	3.3	13
142	Coping strategies for antidepressant side effects: An Internet survey. Journal of Affective Disorders, 2012, 143, 89-94.	4.1	13
143	Suzaku X-ray observations of the mixed-morphology supernova remnant CTB 1. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	13
144	Comparison of emotional processing assessed with fear conditioning by interpersonal conflicts in patients with depression and schizophrenia. Psychiatry and Clinical Neurosciences, 2019, 73, 116-125.	1.8	13

#	Article	IF	CITATIONS
145	A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. Journal of Clinical Psychiatry, 2017, 78, e844-e851.	2.2	13
146	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophrenia Research, 2015, 164, 149-154.	2.0	12
147	Reduction of cross-talks between circuit and sensor layer in the Kyoto's X-ray astronomy SOI pixel sensors with Double-SOI wafer. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2016, 831, 61-64.	1.6	12
148	Performance of the Silicon-On-Insulator pixel sensor for X-ray astronomy, XRPIX6E, equipped with pinned depleted diode structure. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2019, 924, 468-472.	1.6	12
149	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia. American Journal of Geriatric Psychiatry, 2012, , 1.	1.2	12
150	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. Journal of Psychiatry and Neuroscience, 2022, 47, E1-E10.	2.4	12
151	Absence of evidence that the pro re nata regimen confers benefit. International Clinical Psychopharmacology, 2013, 28, 228-237.	1.7	11
152	Poly- <small>L</small> -arginine-Induced Internalization of Tight Junction Proteins Increases the Paracellular Permeability of the Caco-2 Cell Monolayer to Hydrophilic Macromolecules. Biological and Pharmaceutical Bulletin, 2013, 36, 432-441.	1.4	11
153	Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine. Journal of Clinical Pharmacology, 2016, 56, 1111-1119.	2.0	11
154	Time Variability of Nonthermal X-Ray Stripes in Tycho's Supernova Remnant with Chandra. Astrophysical Journal, 2020, 894, 50.	4.5	11
155	Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. Neuro-Oncology, 2021, 23, 945-954.	1.2	11
156	Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage. Journal of Clinical Psychiatry, 2016, 77, 1381-1390.	2.2	11
157	Threshold of Dopamine D _{2/3} Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, e1557-e1563.	2.2	11
158	Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacology Bulletin, 2008, 41, 80-102.	0.0	11
159	Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults. BMC Medical Imaging, 2009, 9, 12.	2.7	10
160	Are Antipsychotic Prescribing Patterns Different in Older and Younger Adults?: A Survey of 1357 Psychiatric Inpatients in Toronto. Canadian Journal of Psychiatry, 2010, 55, 248-254.	1.9	10
161	Patient's trust in their psychiatrist: a cross-sectional survey. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 603-608.	3.2	10
162	Baseline Difference Between Patients' and Clinicians' Rated Illness Severity Scores and Subsequent Outcomes in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2014, 34, 297-302.	1.4	10

#	Article	IF	CITATIONS
163	Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. American Journal of Geriatric Psychiatry, 2017, 25, 708-716.	1.2	10
164	Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study. Psychiatry Research, 2017, 251, 20-25.	3.3	10
165	Neuroscienceâ€based Nomenclature: What is it, why is it needed, and what comes next?. Psychiatry and Clinical Neurosciences, 2018, 72, 50-51.	1.8	10
166	Kampo, A Japanese Traditional Medicinal System for Psychiatric Conditions: A Narrative Review. Pharmacopsychiatry, 2019, 52, 251-260.	3.3	10
167	Impact of subjective vs. objective remission status on subjective cognitive impairments in depression. Journal of Affective Disorders, 2019, 246, 99-104.	4.1	10
168	Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry, 2021, 54, 60-67.	3.3	10
169	Protective effects of oral glutathione on fasting-induced intestinal atrophy through oxidative stress. World Journal of Gastroenterology, 2017, 23, 6650-6664.	3.3	10
170	Antipsychotics-induced hypersensitivity of visual perception. European Psychiatry, 2006, 21, 343-344.	0.2	9
171	Magnitude of Rater Differences in Assessment Scales for Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 607-611.	1.4	9
172	Resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan. Schizophrenia Research, 2016, 171, 92-96.	2.0	9
173	Low sense of coherence is associated with anxiety among adults: Results based on data from all 47 prefectures of Japan. Comprehensive Psychiatry, 2018, 86, 131-136.	3.1	9
174	lonization age of iron ejecta in the Galactic TypeÂla supernova remnant G306.3â^'0.9. Publication of the Astronomical Society of Japan, 2019, 71, .	2.5	9
175	Towards safer risperidone prescribing in Alzheimer's disease. British Journal of Psychiatry, 2021, 218, 268-275.	2.8	9
176	Continuous versus extended antipsychotic dosing in schizophrenia: Less is more. Behavioural Brain Research, 2021, 401, 113076.	2.2	9
177	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neurolmage: Clinical, 2021, 32, 102852.	2.7	9
178	Fluctuating PEEP versus conventional PEEP in diffuse and unilateral lung injury induced by oleic acid. Acta Anaesthesiologica Scandinavica, 1988, 32, 420-425.	1.6	8
179	The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions. Schizophrenia Research, 2012, 141, e1-e24.	2.0	8
180	Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data. Schizophrenia Research, 2013, 150, 373-379.	2.0	8

#	Article	IF	Citations
181	Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. General Hospital Psychiatry, 2014, 36, 690-693.	2.4	8
182	Successful withdrawal from antipsychotic treatment in elderly male inpatients with schizophreniaâ€"Description of four cases and review of the literature. Psychiatry Research, 2014, 220, 152-157.	3.3	8
183	Dependence on benzodiazepines in patients with panic disorder: A crossâ€sectional study. Psychiatry and Clinical Neurosciences, 2015, 69, 93-99.	1.8	8
184	Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2489-2496.	2.2	8
185	A Possible Role of Takotsubo Cardiomyopathy in Ventricular Fibrillation During Delirium Tremens: A Case Report and Literature Review. Psychosomatics, 2018, 59, 293-297.	2.5	8
186	Prediction Model of Serum Lithium Concentrations. Pharmacopsychiatry, 2018, 51, 82-88.	3.3	8
187	Search for thermal X-ray features from the Crab nebula with the Hitomi soft X-ray spectrometer. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	8
188	Hitomi X-ray studies of giant radio pulses from the Crab pulsar. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	8
189	Early Improvement of Specific Symptoms Predicts Subsequent Recovery in Bipolar Depression. Journal of Clinical Psychiatry, 2017, 78, e146-e151.	2.2	8
190	Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease. Journal of Clinical Psychiatry, 2017, 78, e1204-e1210.	2.2	8
191	Patterns of functional connectivity alterations induced by alcohol reflect somatostatin interneuron expression in the human cerebral cortex. Scientific Reports, 2022, 12, 7896.	3.3	8
192	Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 160-161.	4.8	7
193	Subjective recognition of adverse events with antidepressant in people with depression: A prospective study. Journal of Affective Disorders, 2011, 135, 347-353.	4.1	7
194	Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics. International Clinical Psychopharmacology, 2013, 28, 261-266.	1.7	7
195	Cardiac Sudden Death in Psychiatric Patients. Canadian Journal of Psychiatry, 2015, 60, 203-205.	1.9	7
196	Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. Psychopharmacology, 2016, 233, 4003-4010.	3.1	7
197	Radiologic and histologic features of the T2 hyperintensity rim of meningiomas on magnetic resonance images. Neuroradiology Journal, 2017, 30, 48-56.	1.2	7
198	Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey. Pharmacopsychiatry, 2017, 50, 264-269.	3.3	7

#	Article	IF	Citations
199	Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. Journal of Psychiatric Research, 2019, 117, 1-6.	3.1	7
200	Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCT s. Acta Psychiatrica Scandinavica, 2019, 139, 108-116.	4.5	7
201	Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. Schizophrenia Research, 2020, 215, 173-180.	2.0	7
202	Temporal and spatial variation of synchrotron X-ray stripes in Tycho's supernova remnant. Publication of the Astronomical Society of Japan, 2020, 72, .	2.5	7
203	Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience. Clinical Psychopharmacology and Neuroscience, 2016, 14, 115-116.	2.0	7
204	AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding. Schizophrenia Research, 2022, 243, 98-109.	2.0	7
205	Clozapine Once-Daily Versus Divided Dosing Regimen. Journal of Clinical Psychopharmacology, 2022, 42, 163-168.	1.4	7
206	An Open-Label Trial of Discontinuing Benzodiazepines in Patients With Chronic Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 401-403.	1.4	6
207	Plasma substance P level in patients with schizophrenia: A crossâ€sectional study. Psychiatry and Clinical Neurosciences, 2011, 65, 526-528.	1.8	6
208	How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. Journal of Psychiatric Research, 2011, 45, 1083-1088.	3.1	6
209	Lack of Effect of Risperidone or Olanzapine Dose Reduction on Metabolic Parameters, Prolactin, and Corrected QT Interval in Stable Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2014, 34, 517-520.	1.4	6
210	Effectiveness of Saikokaryukotsuboreito (Herbal Medicine) for Antipsychotic-Induced Sexual Dysfunction in Male Patients with Schizophrenia: A Description of Two Cases. Case Reports in Psychiatry, 2014, 2014, 1-3.	0.5	6
211	Postural sway and flexibility in patients with schizophrenia-spectrum disorders: A cross-sectional study. Asian Journal of Psychiatry, 2016, 19, 14-18.	2.0	6
212	Vestibular stimulation improves insight into illness in schizophrenia spectrum disorders. Psychiatry Research, 2017, 251, 333-341.	3.3	6
213	Representativeness of clinical PET study participants with schizophrenia: A systematic review. Journal of Psychiatric Research, 2017, 88, 72-79.	3.1	6
214	Dietary Nitrite Attenuates Elastase-Induced Pulmonary Emphysema in a Mouse Model. Biological and Pharmaceutical Bulletin, 2018, 41, 1818-1823.	1.4	6
215	Alteration in AMPA receptor subunit expression and receptor binding among patients with addictive disorders: A systematic review of human postmortem studies. Neuropsychopharmacology Reports, 2019, 39, 148-155.	2.3	6
216	Radiation damage effects on double-SOI pixel sensors for X-ray astronomy. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2020, 978, 164435.	1.6	6

#	Article	IF	CITATIONS
217	How common is pulmonary embolism compared to acute myocardial infarction among patients with severe mental illnesses? Psychiatry and Clinical Neurosciences, 2020, 74, 277-278.	1.8	6
218	Translational medicine of the glutamate AMPA receptor. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2021, 97, 1-21.	3.8	6
219	A Tipping Point in Drug Dosing in Late-Life Schizophrenia. Current Psychiatry Reports, 2011, 13, 225-233.	4.5	5
220	Fear Conditioning Induced by Interpersonal Conflicts in Healthy Individuals. PLoS ONE, 2015, 10, e0125729.	2.5	5
221	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 207-213.	4.8	5
222	Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. Neuropsychopharmacology Reports, 2020, 40, 138-149.	2.3	5
223	Low-energy X-ray performance of SOI pixel sensors for astronomy, "XRPIX― Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2021, 986, 164745.	1.6	5
224	Selective Serotonin Reuptake Inhibitor–Induced Spermatorrhea in 2 Patients. Journal of Clinical Psychiatry, 2009, 70, 1192-1193.	2.2	5
225	Frontostriatal Structural Connectivity and Striatal Glutamatergic Levels in Treatment-Resistant Schizophrenia: An Integrative Analysis of DTI and 1H-MRS. Schizophrenia Bulletin Open, 2020, 1, .	1.7	5
226	Two Case Reports of Successful Prevention of Overdosing in Borderline Patients. Psychiatry (New) Tj ETQq0 0 0	rgBT /Ove 0.7	rlogk 10 Tf 50
227	Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. Pharmacopsychiatry, 2015, 48, 286-291.	3 . 3	4
228	Inducible and neuronal nitric oxide synthases exert contrasting effects during rat intestinal recovery following fasting. Experimental Biology and Medicine, 2017, 242, 762-772.	2.4	4
229	Psychopharmacology in Japan. Journal of Clinical Psychopharmacology, 2018, 38, 415-419.	1.4	4
230	Glimpse of the highly obscured HMXB IGR J16318â^'4848 with Hitomi. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	4
231	Evaluation of Kyoto's event-driven X-ray astronomical SOI pixel sensor with a large imaging area. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2019, 924, 400-403.	1.6	4
232	Lower Proportion of Fatal Arrhythmia in Sudden Cardiac Arrest Among Patients With Severe Mental Illness Than Nonpsychiatric Patients. Psychosomatics, 2020, 61, 24-30.	2.5	4
233	Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A crossâ€sectional study. Neuropsychopharmacology Reports, 2020, 40, 232-238.	2.3	4
234	Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia. Journal of Clinical Psychiatry, 2018, 80, .	2.2	4

#	Article	IF	Citations
235	High-resolution X-ray study of supernova remnant J0453.6â°6829 with unusually high forbidden-to-resonance ratio. Publication of the Astronomical Society of Japan, 2022, 74, 757-766.	2.5	4
236	Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1141-1142.	4.8	3
237	Impacts of Switching Antidepressants After Successful Electroconvulsive Therapy on the Maintenance of Clinical Remission in Patients With Treatment-Resistant Depression. Journal of ECT, 2009, 25, 178-181.	0.6	3
238	Deficit status in bipolar disorder: Investigation on prevalence rate and description of seven cases. Journal of Affective Disorders, 2012, 143, 248-252.	4.1	3
239	Discrepancy in Psychological Attitudes Toward Living Donor Liver Transplantation Between Recipients and Donors. Transplantation, 2015, 99, 2551-2555.	1.0	3
240	Development of a Transnasal Delivery System for Recombinant Human Growth Hormone (rhGH): Effects of the Concentration and Molecular Weight of Poly-L-arginine on the Nasal Absorption of rhGH in Rats. Biological and Pharmaceutical Bulletin, 2016, 39, 329-335.	1.4	3
241	Long-term proton pump inhibitor use after <i>Helicobacter pylori</i> eradication may create a gastric environment for <i>N</i> -nitrosamine formation and gastric cancer development. Gut, 2019, 68, 1131.2-1131.	12.1	3
242	Etiology of outâ€ofâ€hospital cardiac arrest in psychiatric patients: Chart review. Psychiatry and Clinical Neurosciences, 2019, 73, 243-247.	1.8	3
243	Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents: A Case Report. Clinical Neuropharmacology, 2020, 43, 81-83.	0.7	3
244	Diffuse Large B-Cell Lymphoma of the Central Nervous System Manifesting with Intratumoral Hemorrhage: A Case Report and Literature Review. World Neurosurgery, 2020, 143, 490-494.	1.3	3
245	Proton radiation hardness of x-ray SOI pixel sensors with pinned depleted diode structure. Journal of Astronomical Telescopes, Instruments, and Systems, 2021, 7, .	1.8	3
246	Whether to Increase or Maintain Dosage of Mirtazapine in Early Nonimprovers With Depression. Journal of Clinical Psychiatry, 2015, 76, 434-439.	2.2	3
247	Influence of alcohol and acetaldehyde on cognitive function: findings from an alcohol clamp study in healthy young adults. Addiction, 2022, 117, 934-945.	3.3	3
248	A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication. Psychopharmacology Bulletin, 2008, 41, 164-70.	0.0	3
249	Prognostic impact of <i>PDGFRA</i> gain/amplification and <i>MGMT</i> promoter methylation status in patients with <i>IDH</i> wild-type glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.7	3
250	Should adjunctive antipsychotic treatment be continued in remitted patients with depression?. Psychiatry and Clinical Neurosciences, 2009, 63, 126-126.	1.8	2
251	Depression Severity and Effect of Antidepressant Medications. JAMA - Journal of the American Medical Association, 2010, 303, 1596.	7.4	2
252	Analysis of Antipsychotic Dose Reduction. American Journal of Psychiatry, 2010, 167, 994-994.	7.2	2

#	Article	IF	Citations
253	An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2013, 9, 1553.	2.2	2
254	Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatry Research, 2014, 218, 244-246.	3.3	2
255	Psychotic Symptoms Associated With Varenicline in a Patient With Alcohol and Nicotine Dependence. Journal of Clinical Psychopharmacology, 2017, 37, 627-628.	1.4	2
256	Psychological dependence on antidepressants in patients with panic disorder. International Clinical Psychopharmacology, 2017, 32, 36-40.	1.7	2
257	Discrepancies Between Nomenclature and Indications of Psychotropics. Pharmacopsychiatry, 2019, 52, 175-179.	3.3	2
258	Concomitant use of alcohol and benzodiazepine hypnotics in psychiatric outpatients. International Clinical Psychopharmacology, 2019, 34, 291-297.	1.7	2
259	P.362 Antipsychotic treatment for the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. European Neuropsychopharmacology, 2019, 29, S258-S259.	0.7	2
260	Optical blocking performance of CCDs developed for the X-ray Astronomy Satellite XRISM. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2020, 978, 164374.	1.6	2
261	Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J). PLoS ONE, 2020, 15, e0234864.	2.5	2
262	Development of a risk stratification scoring system for deep vein thrombosis upon psychiatric admission. Journal of Psychosomatic Research, 2021, 147, 110540.	2.6	2
263	Increasing trend in the prevalence of alcoholâ€sensitive individuals with alcohol use disorder over the past 40 years. Psychiatry and Clinical Neurosciences, 2022, 76, 32-33.	1.8	2
264	Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder. PLoS ONE, 2021, 16, e0260431.	2.5	2
265	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. British Journal of Clinical Pharmacology, 2022, 88, 3341-3350.	2.4	2
266	X-ray radiation damage effects on double-SOI pixel detectors for the future astronomical satellite FORCE. Journal of Astronomical Telescopes, Instruments, and Systems, 2022, 8, .	1.8	2
267	Strict use of terminology: Reply to Dr Toda. Psychiatry and Clinical Neurosciences, 2009, 63, 430-431.	1.8	1
268	Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. Psychiatry Research, 2015, 228, 26-30.	3.3	1
269	A questionnaire survey of Japanese non-psychiatrists' attitudes on management of depression in a general hospital. Asian Journal of Psychiatry, 2015, 15, 73-74.	2.0	1
270	Relapse of ileus in patients with psychiatric disorders: A 2-year chart review. General Hospital Psychiatry, 2016, 38, 31-36.	2.4	1

#	Article	IF	CITATIONS
271	No Association of Caffeinated Beverage or Caffeine Intake with Prevalence of Urinary Incontinence Among Middle-Aged Japanese Women: A Multicenter Cross-Sectional Study. Journal of Women's Health, 2017, 26, 860-869.	3.3	1
272	T108. AMPA Receptor Subunit Expression and Receptor Binding in Patients With Major Depressive Disorder: A Systematic Review of Postmortem Studies. Biological Psychiatry, 2018, 83, S170.	1.3	1
273	Measurement of Charge Cloud Size in X-Ray SOI Pixel Sensors. IEEE Transactions on Nuclear Science, 2019, 66, 1897-1905.	2.0	1
274	Improvement of clinical clerkship for medical students by incorporating ideas from junior residents: A feasibility study. Asian Journal of Psychiatry, 2019, 44, 110-111.	2.0	1
275	Mortality from sepsis among patients with schizophrenia and mood disorders in an intensive care unit: A chart review. Psychiatry Research, 2019, 279, 372-373.	3.3	1
276	Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids. Acta Psychiatrica Scandinavica, 2020, 142, 242-248.	4.5	1
277	Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials. Asian Journal of Psychiatry, 2020, 54, 102250.	2.0	1
278	Effects of 30â€minute single sessions of yoga and Pilates on frailty in patients with psychiatric disorders: A pilot randomized controlled trial. International Journal of Geriatric Psychiatry, 2021, 36, 618-620.	2.7	1
279	Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110161.	2.7	1
280	Prescription patterns in patients with schizophrenia who discontinued longâ€acting injectable antipsychotics: A chartâ€review. Psychiatry and Clinical Neurosciences, 2021, 75, 184-185.	1.8	1
281	Development of diagnostic criteria and severity scale for polydipsia: A systematic literature review and well-experienced clinicians' consensus. Psychiatry Research, 2021, 297, 113708.	3.3	1
282	Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis. Pharmacopsychiatry, 2021, 54, 106-116.	3.3	1
283	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. Schizophrenia Research, 2022, 241, 113-115.	2.0	1
284	Drug Combinations for Mood Disorders and Physical Comorbidities That Need Attention: A Cross-Sectional National Database Survey. Pharmacopsychiatry, 2022, 55, 157-162.	3.3	1
285	Electrical stimulation of the gastrointestinal muscle and nerve in surgery of the gastrointestinal tract. Gastroenterologia Japonica, 1968, 3, 427-427.	0.3	0
286	Simplifying psychotropic medication regimen into a single night dosing and reducing the dose for patients with chronic, stable schizophrenia. International Clinical Psychopharmacology, 2004, 19, 183.	1.7	0
287	Dose reduction of antipsychotic agents ameliorates paroxysmal perceptual alteration: a controlled study. International Clinical Psychopharmacology, 2004, 19, 180-181.	1.7	0
288	A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder. International Clinical Psychopharmacology, 2005, 20, A16.	1.7	0

#	Article	IF	CITATIONS
289	Reply to Comments by Dr Magalhães. Journal of Clinical Psychopharmacology, 2007, 27, 318-319.	1.4	O
290	P.2.a.018 Persistence and compliance to antidepressant treatment in patients with depression: a chart review. European Neuropsychopharmacology, 2009, 19, S370-S371.	0.7	0
291	P.3.c.030 Low dose versus standard dose of antipsychotics for relapse prevention in schizophrenia: a meta-analysis. European Neuropsychopharmacology, 2009, 19, S527-S528.	0.7	0
292	LOW DOSE VS. STANDARD DOSE OF ANTIPSYCHOTICS FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Schizophrenia Research, 2010, 117, 503-504.	2.0	0
293	Potential risks of adjunctive use of atypical antipsychotic drugs for the treatment of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 435-436.	4.8	0
294	Potentials and current limitations of brain stimulation therapies to accelerate antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 439-440.	4.8	0
295	P.2.a.008 Why do patients not tell the truth to their physician? A large-scale internet survey. European Neuropsychopharmacology, 2011, 21, S358-S359.	0.7	0
296	P.3.c.063 The evolution of antipsychotic switch and polypharmacy in natural practice: a longitudinal perspective. European Neuropsychopharmacology, 2011, 21, S505.	0.7	0
297	Balancing Potential Risks and Benefits of Adjunctive Use of Aripiprazole With Risperidone for the Treatment of Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 136-137.	1.4	0
298	E-030â€Multi-staged Embolisation of Neonatal Vein of Galen Aneurysmal Malformation through a 3-French Sheath. Journal of NeuroInterventional Surgery, 2013, 5, A47.1-A47.	3.3	0
299	Discovery of a recombination dominant plasma: a relic of a giant flare of Sgr A*?. Proceedings of the International Astronomical Union, 2013, 9, 349-353.	0.0	0
300	Timing of Adjunctive Therapy in the Treatment of Depression: A Chart Review. Pharmacopsychiatry, 2014, 47, 259-262.	3.3	0
301	Prescription patterns for depression among consultation–liaison psychiatrists and nonâ€psychiatrists: a chart review. International Journal of Geriatric Psychiatry, 2016, 31, 1084-1085.	2.7	0
302	194. Exploring Neural Basis of Emotional Cognition Using Fear Conditioning by Interpersonal Conflicts in Patients with Schizophrenia. Biological Psychiatry, 2017, 81, S80-S81.	1.3	0
303	AMPA receptor subunit expression and receptor binding in patients with addiction: a systematic review of postmortem studies. European Neuropsychopharmacology, 2017, 27, S756-S757.	0.7	0
304	Risk factors of delirium following electroconvulsive therapy: a systematic review. European Neuropsychopharmacology, 2017, 27, S857.	0.7	0
305	Mood stabilizers as an Achilles' heel for indicationâ€based nomenclature and roles of Neuroscienceâ€based Nomenclature. Psychiatry and Clinical Neurosciences, 2018, 72, 854-855.	1.8	0
306	Recycling and Energy Recovery by Municipal Solid Waste Carbonization Fuel System. Nihon Enerugi Gakkaishi/Journal of the Japan Institute of Energy, 2018, 97, 252-260.	0.2	0

#	Article	IF	CITATIONS
307	ANGI-06. FUNCTION OF FORMIN-LIKE 1 (FMNL1) IN GLIOBLASTOMA MULTIFORME. Neuro-Oncology, 2019, 21, vi31-vi31.	1.2	0
308	PATH-50. ROUTINE MOLECULAR DIAGNOSIS OF GLIOMA PATIENTS USING A GLIOMA-SPECIFIC NGS PANEL. Neuro-Oncology, 2019, 21, vi154-vi155.	1.2	0
309	COT-14 CLINICAL FEATURES OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology Advances, 2019, 1, ii43-ii43.	0.7	0
310	MPC-15 FEASIBILITY OF GLIOMA SPECIFIC ONCOPANEL IN THE DIAGNOSIS OF GLIOMA. Neuro-Oncology Advances, 2019, 1, ii24-ii24.	0.7	0
311	P.529 Prescription patterns of psychotropic drugs in patients who were receiving steroidal anti-inflammatory drugs: analysis of Japanese national prescription data. European Neuropsychopharmacology, 2019, 29, S373-S374.	0.7	O
312	T166. VISUALIZATION OF AMPA RECEPTORS IN PATIENTS WITH SCHIZOPHRENIA AND DEPRESSION: THE FIRST PET IMAGING STUDY. Schizophrenia Bulletin, 2020, 46, S294-S295.	4.3	0
313	M23. ALTERATION OF REGIONAL CEREBRAL BLOOD FLOW MEASURED BY ARTERIAL SPIN LABELING IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S142-S142.	4.3	O
314	Visualization of AMPA Receptors in Patients With Depression, Bipolar Disorder, and Schizophrenia: The First PET Imaging Study. Biological Psychiatry, 2020, 87, S113.	1.3	0
315	Pre-existing psychiatric disorder is related to lower mortality from road traffic accident: A Japanese nationwide retrospective cohort study. Injury, 2021, 52, 1390-1395.	1.7	O
316	Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. Clinical Psychopharmacology and Neuroscience, 2021, 19, 773-779.	2.0	0
317	Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?. , 2013, , 81-107.		0
318	Factor Structure of the Targeted Inventory on Problems in Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2013, 11, 18-23.	2.0	0
319	Characteristic findings of perianal lesions in Japanese patients with Crohn's disease Nihon Daicho Komonbyo Gakkai Zasshi, 1987, 40, 369-379.	0.0	O
320	LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA. Neuro-Oncology, 2020, 22, iii370-iii370.	1.2	0
321	LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION. Neuro-Oncology, 2020, 22, iii372-iii372.	1.2	0